Literature DB >> 6442656

In vitro and in vivo activity of various antibiotics against Listeria monocytogenes type 4b.

A E Hawkins, R Bortolussi, A C Issekutz.   

Abstract

Inadequate guidelines for the treatment of neonatal listeriosis led us to evaluate various antibiotics in a newborn rat model of Listeria monocytogenes type 4b sepsis. Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC based on 99.9% killing), expressed as micrograms/ml, were determined for: ampicillin (MIC 0.46/MBC 3.20); ampicillin with subinhibitory concentrations of gentamicin (0.24/not done); erythromycin (0.14/3.59); gentamicin (0.38/1.11); gentamicin with subinhibitory concentrations of ampicillin (0.235/ND); piperacillin (2.7/16.8); rifampin (0.026/0.094); sulfamethoxazole (SMZ 47.5/ND); SMZ with subinhibitory concentrations of trimethoprim (0.74/1.48); trimethoprim (TMP 0.12/ND); and TMP with subinhibitory concentrations of SMZ (0.04/0.08). In the in vivo model, rats were challenged intraperitoneally with 2 X 10(6) cfu of L. monocytogenes at 3 days-of-age. Antibiotics (ampicillin, ampicillin + gentamicin, erythromycin, piperacillin or TMP/SMZ) were given every 12 h for 2 days starting on day 5 of life while rifampin was given once daily for 2 days. Survival tabulations and spleen cultures were done on day 8 of life. All animals who received antibiotics had better survival than the controls given saline (p less than 0.01 for rifampin, erythromycin, TMP/SMZ, ampicillin, ampicillin + gentamicin; p less than 0.05 for piperacillin). Rifampin, erythromycin and TMP/SMZ gave better survival than piperacillin (p less than 0.01). Although ampicillin plus gentamicin were superior to ampicillin alone (p less than 0.01) in reducing the number of organisms in the spleens, rifampin was superior to all regimens in this regard (p less than 0.0005 vs piperacillin, ampicillin, TMP/SMZ; p less than 0.05 vs ampicillin + gentamicin, erythromycin). Rifampin may be a useful addition to other regimens in speeding the elimination of the organism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442656

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  5 in total

1.  Relationship of bacterial growth phase to killing of Listeria monocytogenes by oxidative agents generated by neutrophils and enzyme systems.

Authors:  R Bortolussi; C M Vandenbroucke-Grauls; B S van Asbeck; J Verhoef
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

2.  A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria.

Authors:  Peter Spanogiannopoulos; Nicholas Waglechner; Kalinka Koteva; Gerard D Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

3.  Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study.

Authors:  Yaakov Dickstein; Yonatan Oster; Orit Shimon; Lior Nesher; Dafna Yahav; Yonit Wiener-Well; Regev Cohen; Ronen Ben-Ami; Miriam Weinberger; Galia Rahav; Yasmin Maor; Michal Chowers; Ran Nir-Paz; Mical Paul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-10       Impact factor: 3.267

4.  In vitro antimicrobial susceptibility of Listeria monocytogenes isolated in the UK and other Listeria species.

Authors:  A P MacGowan; H A Holt; M J Bywater; D S Reeves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

Review 5.  Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

Authors:  E M Jones; A P MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.